Ciliated muconodular papillary tumor of the lung: a case report and literature review
- 18 Downloads
Ciliated muconodular papillary tumor (CMPT) of the lung is characterized as a peripheral low-grade malignant tumor with ciliated columnar cells and goblet cells with basaloid cell proliferation. Herein, we report on a case of CMPT with a radiologically abnormal shadow which was reminiscent of adenocarcinoma. The patient underwent right S6 + S8a segmentectomy because an intraoperative biopsy suggested CMPT, the malignancy of which was difficult to distinguish; however, the tumor was small and located in the peripheral lung. Many details of this tumor remain unclear, as CMPT is a rare tumor with few reports. CMPT has therefore not yet been classified by the WHO. In this report, we will consider the characteristics of CMPT and treatment based on our case and previous case reports.
KeywordsCiliated muconodular papillary tumor Low-grade malignancy Lung tumor CMPT Segmentectomy
Compliance with ethical standards
Conflict of interest
The authors have declared that no conflict of interest exists.
- 1.Ishikawa Y. Ciliated muconodular papillary tumor of the peripheral lung: benign or malignant? Pathol Clin Med (in Japanese). 2002;20:964–5.Google Scholar
- 6.Chuang HW, Liao JB, Chang HC, Wang JS, Lin AL, Hsieh PP. Ciliated muconodular papillary tumor of the lung: a newly defined peripheral pulmonary tumor with conspicuous mucin pool mimicking colloid adenocarcinoma: a case report and review of literature. Pathol Int. 2014;64:352–7.CrossRefGoogle Scholar
- 9.Ishikawa M, Sumitomo S, Imamura N, Nishida T, Mineura K, Ono K. Ciliated muconodular papillary tumor of the lung: report of five cases. J Surg Case Rep. 2016;8:1–4.Google Scholar
- 12.Segawa M, Toki Y, Shimada Y, Tatsu H, Saito K, Touge M. Ciliated muconodular papillary tumor of the lung. Jpn J Thoracic Cardiovasc Surg (in Japanese). 2017;70:782–5.Google Scholar
- 15.Kim L, Kim YS, Lee JS, Choi SJ, Park IS, Hanet JY, et al. Ciliated muconodular papillary tumor of the lung harboring BRAF V600E mutation and p16INK4a overexpression without proliferative activity may represent an example of oncogene-induced senescence. J Thorac Dis. 2017;9:E1039–E10441044.CrossRefGoogle Scholar